Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.89 +0.01 (+0.09%)
At close: Oct 1, 2026 · 4:00 PM EDT

Drugs Made In America Acquisition (DMAA) Accumulated Expenses (2024 - 2026)

Updated

Drugs Made In America Acquisition's Accumulated Expenses came in at $10,500 for Q2 2026, down 92.9% from $147,453 a year earlier.

Analysis

Drugs Made In America Acquisition (DMAA) Accumulated Expenses (2024 - 2026) Analysis & Trends

At the end of FY2024, Drugs Made In America Acquisition's Accumulated Expenses was $77,280.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 BlackRock 164.13 Bn 110.49 Bn -
2 Spdr Gold Trust 133.82 Bn -424.18 Bn -
3 Blackstone 84.08 Bn 79.01 Bn -
4 Brookfield 82.97 Bn -82.41 Bn 4.47 Bn
5 Kkr 81.05 Bn 47.53 Bn -
6 Brookfield Asset Management 71.64 Bn 67.88 Bn -
7 Apollo Global Management 65.67 Bn 3.35 Bn 10.56 Bn
8 Wheaton Precious Metals 61.89 Bn 57.32 Bn 687.86 Mn
9 Franco Nevada 46.13 Bn 43.49 Bn 451.00 Mn
10 Drugs Made In America Acquisition 335.55 Mn 335.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10,500.00
Sep 30, 2025 302,623.00
Jun 30, 2025 147,453.00
Mar 31, 2025 132,483.00
Dec 31, 2024 77,280.00
API Access

Drugs Made In America Acquisition Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=DMAA&period=max&api_key=YOUR_API_KEY